IP Library Granted Patent US 9,034,646
Granted Patent B2
US 9,034,646 · App. 13/684,746 · Granted May 19, 2015

Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof

Inventors: Thierry Burnouf (Lille, FR); Cheng-Yao Su (Taipei, TW)
Assignee: ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.
C12N5/0018A61K38/1808A61K38/1841A61K38/30A61K35/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,034,646
App. No.
13/684,746
Granted
May 19, 2015
Kind
B2
Abstract

The invention concerns human platelet extracts rich in growth factors (PGF) for wound healing and stem cell expansion. Accordingly the subject invention relates to a virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF, which is preferably enriched in TGF, IGF and EGF-rich. The present invention further concerns a method for obtaining a platelet lysate comprising the steps of contacting a starting platelet concentrate with a solvent and/or a detergent, incubating the starting platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., optionally removing the solvent and/or the detergent by oil extraction and obtaining an aqueous protein phase, and incubating the solvent and/or detergent-treated platelet concentrate or the aqueous protein phase with charcoal.

Claims (19)

1. A method for preparing a virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF comprising:

a) containing a starting platelet concentrate with a solvent and a detergent;

b) incubating for a period of at least 5 minutes to 6 hours, at a physiological pH or at a pH ranging from pH 6.8 to 8.2, and at a temperature within the range of from 2° C. to 50° C.;

c) removing the solvent and detergent by oil extraction and obtaining an aqueous protein phase;

d) mixing activated charcoal with the aqueous protein phase obtained in c);

e) centrifuging the mixture of d) to pellet the charcoal; and

f) recovering the supernatant from e), wherein the supernatant is virally-inactivated and depleted of PDGF and VEGF.

2. The method of claim 1 wherein the solvent is selected from the group consisting of di- or trialkylphosphates, di- or trialkylphosphates with different alkyl chains.

3. The method according to claim 2 , wherein the solvent is the tri-n-butylphosphate (TnBP).

4. The method of claim 1 wherein the detergent is selected from the group consisting of polyoxyethylene derivatives of fatty acids, partial esters of sorbitol anhydrides, non-ionic detergents, sodium deoxycholate and sulfobetaines.

5. The method according to claim 4 , wherein the detergent is oxyethylated alkylphenol or polysorbate 80.

6. The method of claim 1 wherein the concentration of both the solvent and detergent in step a) ranges from 0.2 to 5% in volume with respect to the volume of the starting platelet concentrate.

7. The method according to claim 1 , wherein oil extraction is performed with a pharmaceutical grade oil, the oil being used in an amount of from 2 to 20 weight % based on the weight of the mixture of the platelet concentrate with the solvent and the detergent.

8. The method according to claim 7 , wherein the oil is in the amount of from 5 to 15 weight %.

9. The method according to claim 8 , wherein the oil is in the amount of from 5 to 10 weight %.

10. The method according to claim 1 , wherein the activated charcoal is in an amount of from 50 to 250 g/l of said aqueous protein phase.

11. The method according to claim 1 , further comprising centrifuging after step c) to pellet and remove any cell debris or insoluble material and recover the supernatant.

12. The method according to claim 1 , wherein the starting platelet concentrate of step a) is prepared by at least one of apheresis and buffy-coat isolation from whole blood.

13. The method according to claim 1 , wherein the starting platelet concentrate of step a) is obtained from pool platelet concentrates.

Assignments (2)
CHANGE OF NAME Recorded Mar 16, 2015
From: GWOWEI TECHNOLOGY CO., LTD.
To: ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.
Reel/Frame 035169/0088 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2013
From: BURNOUF, THIERRY; SU, CHENG-YAO
To: GWOWEI TECHNOLOGY CO., LTD.
Reel/Frame 030173/0699 →
Priority Claims (1)
EP 10163843 · May 25, 2010 · regional
Continuity (2)
Continuation PCTIB2011052278 · May 25, 2011
Related Publication 20130143810A1 · Jun 6, 2013